Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Decade in review—migraine

Incredible progress for an era of better migraine care

Nature Reviews Neurology volume 11, pages 621–622 (2015)Cite this article

Subjects

In the past 10 years, the realization that migraine is a brain disorder rather than a vascular disorder has facilitated development of various treatments, ranging from innovative immunopharmaceuticals through to neurostimulation. Many clinical trials have been successful, and such considerable progress holds promise for the coming decade of migraine treatment.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386, 743–800 (2015).

  2. Amin, F. M. et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 12, 454–461 (2013).

    Article  Google Scholar 

  3. Maniyar, F. H., Sprenger, T., Monteith, T., Schankin, C. & Goadsby, P. J. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 137, 232–241 (2014).

    Article  Google Scholar 

  4. Hougaard, A., Amin, F., Hauge, A. W., Ashina, M. & Olesen, J. Provocation of migraine with aura using natural trigger factors. Neurology 80, 428–431 (2013).

    Article  Google Scholar 

  5. Akerman, S., Holland, P. & Goadsby, P. J. Diencephalic and brainstem mechanisms in migraine. Nat. Rev. Neurosci. 12, 570–584 (2011).

    Article  CAS  Google Scholar 

  6. Goadsby, P. J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183–187 (1990).

    Article  CAS  Google Scholar 

  7. Goadsby, P. J., Edvinsson, L. & Ekman, R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 23, 193–196 (1988).

    Article  CAS  Google Scholar 

  8. Ho, T. W., Edvinsson, L. & Goadsby, P. J. CGRP and its receptors provide new insights into migraine pathophysiology. Nat. Rev. Neurol. 6, 573–582 (2010).

    Article  CAS  Google Scholar 

  9. Ayata, C., Jin, H., Kudo, C., Dalkara, T. & Moskowitz, M. A. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59, 652–661 (2006).

    Article  CAS  Google Scholar 

  10. Tolner, E. A. et al. From migraine genes to mechanisms. Pain 156 (Suppl. 1), S64–S74 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, and King's Clinical Research Facility, Kings College London, Wellcome Foundation Building, King's College Hospital, London, SE5 9PJ, UK

    Peter J. Goadsby

Authors
  1. Peter J. Goadsby
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter J. Goadsby.

Ethics declarations

Competing interests

The author has received grants and personal fees from Allergan, Amgen and eNeura, and personal fees from Ajinomoto Pharmaceuticals, Akita Biomedical, Alder Biopharmaceuticals, Autonomic Technologies, Avanir Pharmaceuticals, Cipla, CoLucid Pharmaceuticals, Dr Reddy's Laboratories, EMKinetics, Ethicon, Heptares, Lilly, NEJM Journal Watch, Pfizer, Promius Pharma, Teva, UpToDate, Wells Fargo, W. L. Gore & Associates and Zosano Pharma. He has also received personal fees for medicolegal work for individuals. He also has a patent pending for magnetic stimulation for headache.

Supplementary information

Supplementary Table 1

Migraine therapeutics that have been tested in clinical trials (DOC 143 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goadsby, P. Incredible progress for an era of better migraine care. Nat Rev Neurol 11, 621–622 (2015). https://doi.org/10.1038/nrneurol.2015.203

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2015.203

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing